DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

DENTSPLY SIRONA (NASDAQ:XRAY) had its price objective hoisted by stock analysts at Wells Fargo & Company from $12.00 to $13.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s target price would indicate a potential downside of 11.44% from the company’s current price.

A number of other analysts have also commented on XRAY. UBS Group reduced their target price on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Zacks Research downgraded DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a report on Monday, November 10th. Robert W. Baird boosted their target price on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday. Stifel Nicolaus set a $13.00 price target on shares of DENTSPLY SIRONA in a report on Thursday, November 6th. Finally, Mizuho lifted their price target on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 20th. Three investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, DENTSPLY SIRONA has an average rating of “Hold” and a consensus target price of $14.00.

DENTSPLY SIRONA Stock Performance

Shares of XRAY stock opened at $14.68 on Friday. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of -4.89, a price-to-earnings-growth ratio of 1.15 and a beta of 1.01. The company has a debt-to-equity ratio of 1.36, a quick ratio of 0.99 and a current ratio of 1.47. DENTSPLY SIRONA has a one year low of $9.85 and a one year high of $17.34. The company’s 50-day moving average is $12.42 and its 200 day moving average is $12.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 17.62% and a negative net margin of 16.25%.The firm had revenue of $961.00 million during the quarter, compared to the consensus estimate of $926.40 million. During the same quarter in the prior year, the company posted $0.26 EPS. The company’s quarterly revenue was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts expect that DENTSPLY SIRONA will post 1.84 EPS for the current fiscal year.

Insider Activity

In related news, Director Gregory T. Lucier sold 82,200 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Mitsubishi UFJ Trust & Banking Corp boosted its stake in DENTSPLY SIRONA by 1,836.7% during the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 105,938 shares of the medical instruments supplier’s stock valued at $1,344,000 after buying an additional 100,468 shares during the last quarter. Bank of Montreal Can increased its stake in DENTSPLY SIRONA by 8.2% in the 2nd quarter. Bank of Montreal Can now owns 352,524 shares of the medical instruments supplier’s stock worth $5,598,000 after acquiring an additional 26,610 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of DENTSPLY SIRONA by 38.4% during the 3rd quarter. Commonwealth Equity Services LLC now owns 804,934 shares of the medical instruments supplier’s stock worth $10,215,000 after acquiring an additional 223,339 shares in the last quarter. CWM LLC boosted its position in shares of DENTSPLY SIRONA by 84.3% during the 3rd quarter. CWM LLC now owns 420,470 shares of the medical instruments supplier’s stock valued at $5,336,000 after acquiring an additional 192,373 shares during the last quarter. Finally, Advisors Asset Management Inc. boosted its position in shares of DENTSPLY SIRONA by 42.8% during the 3rd quarter. Advisors Asset Management Inc. now owns 348,989 shares of the medical instruments supplier’s stock valued at $4,429,000 after acquiring an additional 104,588 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Trending Headlines about DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Company announced a $120 million restructuring to redirect annual savings into a “Return-to-Growth” plan (innovation, clinical and sales investment), eliminated the dividend and said it will redeploy capital toward debt paydown and share repurchases — a clear priority shift that drove buying interest. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Top-line beat: Q4 net sales of $961M topped Street estimates and rose 6.2% year-over-year, a sign that demand trends held up despite cost issues. Dentsply Sirona’s Q4 CY2025 sales top estimates
• Neutral Sentiment: Analysts nudged price targets higher: Wells Fargo raised its target to $13 with an “equal weight” rating and Robert W. Baird raised its target to $14 with a “neutral” rating — upgrades that signal some analyst confidence but still leave implied downside vs. the current trading level. Analyst Price Target Moves (Benzinga) TickerReport: Baird PT Raise
• Neutral Sentiment: Earnings call and transcripts available for detail — useful for investors who want management commentary on the restructuring, capital allocation and product road map. Earnings Call Transcript
• Negative Sentiment: Reported adjusted EPS of $0.27 missed consensus by $0.01 and the quarter included a GAAP net loss of $146M driven by ~$144M of goodwill/intangible impairments — items that pressure near-term reported profitability. Earnings Miss Coverage (Zacks)
• Negative Sentiment: FY2026 revenue guidance of $3.5B–$3.6B sits below consensus (~$3.7B), signaling a softer top-line outlook even as adjusted EPS guidance of $1.40–$1.50 is roughly in line — the revenue gap is a downside catalyst to monitor. Company Outlook (GlobeNewswire)
• Negative Sentiment: Legal risk: Halper Sadeh LLC has opened a shareholder investigation into possible fiduciary breaches, which could create headline risk and distract management. Halper Sadeh Investigation Notice

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.